Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.
By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross USD 1 Billion in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.
While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.
Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.
Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.
Principal Consultant
Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals preferhormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.
That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.
The endometriosis treatment market size is estimated to cross USD3.55 Billion by 2032.
The endometriosis treatment market is likely to record a value of USD 1.30 Billion in 2022.
Europe is likely to lead the endometriosis treatment market.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Global Market Demand (Size in USD Million) Analysis 2014 to 2018 and Opportunity Assessment, 2019 to 2030 6. Market Background 7. Global Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030, by Drug 7.1. Oral Contraceptives 7.2. Progestins 7.3. NSAIDs 7.4. GnRH Analogues 7.5. LNR to IUDs 7.6. Others 8. Global Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030, by Treatment Type 8.1. Hormonal Therapy 8.2. Pain Management 9. Global Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030, by Distribution Channel 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Drugstores 9.4. E-Commerce 10. Global Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030, by Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. Middle East and Africa (MEA) 11. North America Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 12. Latin America Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 13. Europe Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 14. South Asia Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 15. East Asia Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 16. Oceania Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 17. Middle East and Africa Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 18. Emerging Countries Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 19. USA Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 20. Canada Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 21. Mexico Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 22. Germany Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 23. UK Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 24. France Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 25. Italy Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 26. Spain Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 27. Russia Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 28. Japan Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 29. South Korea Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 30. Australia Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 31. New Zealand Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 32. GCC Countries Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 33. South Africa Market Analysis 2014 to 2018 and Opportunity Assessment 2019 to 2030 34. Market Structure Analysis 35. Competition Analysis 35.1. AbbVie Inc. 35.2. Bayer AG 35.3. AstraZeneca 35.4. Pfizer Inc. 35.5. Teva Pharmaceutical Industries Ltd. 35.6. Ipsen Pharma 35.7. Myovant Sciences 35.8. Endoceutics, Inc. 35.9. Debiopharm Group 35.10. Mayne Pharma Group Limited 35.11. Noven Pharmaceuticals, Inc. 35.12. Sun Pharmaceutical Industries Limited 35.13. Amneal Pharmaceuticals, Inc. 35.14. Mylan N.V. 35.15. Aurobindo Pharma 36. Assumptions and Acronyms Used 37. Research Methodology
Explore Healthcare Insights
View Reports
Endometriosis Treatment Market
